{"id":801521,"date":"2025-01-16T08:07:10","date_gmt":"2025-01-16T13:07:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/"},"modified":"2025-01-16T08:07:10","modified_gmt":"2025-01-16T13:07:10","slug":"predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/","title":{"rendered":"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Initial plans target European clinical trials while providing standard testing to clinicians for individual patients<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe <\/em>\n      <\/p>\n<p>PITTSBURGH, Jan.  16, 2025  (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx\u00ae drug response assay in Europe and expanded availability in the United States. The ChemoFx\u00ae treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time.<\/p>\n<p>The ChemoFx\u00ae drug response assay is a treatment selection marker for chemotherapies that quantifies an individual cancer patients\u2019 <em>in vitro<\/em> tumor response to various chemotherapeutic agents.<\/p>\n<p>\u201cThe drug response results are critical to Predictive Oncology\u2019s live tumor cell platform that uses AI to create predictive models of drug response to streamline and de-risk the drug discovery process,\u201d said Dr. Arlette Uihlein, Senior Vice President of Translational Medicine and Medical Director. \u201cData sets extracted from these models can be applied to clinical trial design as well as biomarker discovery and companion diagnostic development efforts.\u201d<\/p>\n<p>According to the American Cancer Society, nearly 115,000 new gynecological cancer cases are diagnosed in the United States each year with more than 34,000 deaths attributed to these cancers. In Europe, an estimated 250,000 gynecologic cancer cases are diagnosed each year, the most frequent of which are endometrial, cervical and ovarian.<\/p>\n<p>\u201cOf the approximately 150,000 live cell tumor samples that Predictive has in its biobank, nearly half of those specimens are gynecological cancers, and half of those are ovarian,\u201d said Raymond Vennare, Chief Executive officer of Predictive Oncology. \u201cOur artificial intelligence and machine learning platform was validated against 175 FDA-approved drugs and 130 primary samples from ovarian tumors, and the use of those same data sets to build multi-omic models to predict short and long-term survival in ovarian cancer patients speaks for itself.\u201d<\/p>\n<p>By testing multiple chemotherapies on a patients\u2019 cancer cells before treatment selection, the drug response assay helps determine which chemotherapies are more likely to be effective on the tumor and which are less likely to provide benefit to the patient.<\/p>\n<p>Mr. Vennare added, \u201cWhile much can be said about the significance of our biobank for drug discovery, ChemoFx\u00ae not only represents an equally crucial asset for the personalized treatment and care of cancer patients, the development of AI-driven clinical decision support tools in oncology. Both opportunities come with the potential to generate significant short-term revenue and long-term gains. When first developed and introduced to the market, ChemoFx\u00ae generated gross revenues in excess of $25 million annually.\u201d<\/p>\n<p>\n        <strong>About Predictive Oncology<\/strong>\n      <\/p>\n<p>Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company\u2019s proprietary AI\/ML platform has been scientifically validated to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug\/tumor type combinations. Together with the company\u2019s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry\u2019s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA laboratory facilities. Predictive Oncology is headquartered in Pittsburgh, PA.\u00a0<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>For Predictive Oncology (investors):<\/p>\n<p>Tim McCarthy\u00a0\u00a0<\/p>\n<p>LifeSci Advisors, LLC\u00a0\u00a0<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uMBWBU6r71pobPPKH-YtzLsB87rUr_ekvs9XQJ3sjss8QMBgDA-U0pPnVgKp40nB9wUKni5fCA1ybHM-jLk_XvqJxqKOlwL5FkrmYSZVv7Y=\" rel=\"nofollow\" target=\"_blank\">tim@lifesciadvisors.com<\/a>\n      <\/p>\n<p>\n        <strong>Forward-Looking Statements:<\/strong>\u00a0<br \/>Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cwould,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading \u201cRisk Factors\u201d in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWRjMDBiYzgtZjRiYi00NzJlLWJjMWEtZDNlMzBiMDc4N2Q0LTEwMzA3OTk=\/tiny\/Predictive-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx\u00ae drug response assay in Europe and expanded availability in the United States. The ChemoFx\u00ae treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time. The ChemoFx\u00ae drug response assay is a treatment selection marker for chemotherapies that quantifies an individual cancer patients\u2019 in vitro tumor response to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-801521","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx\u00ae drug response assay in Europe and expanded availability in the United States. The ChemoFx\u00ae treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time. The ChemoFx\u00ae drug response assay is a treatment selection marker for chemotherapies that quantifies an individual cancer patients\u2019 in vitro tumor response to &hellip; Continue reading &quot;Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-16T13:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay\",\"datePublished\":\"2025-01-16T13:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/\"},\"wordCount\":752,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/\",\"name\":\"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=\",\"datePublished\":\"2025-01-16T13:07:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/","og_locale":"en_US","og_type":"article","og_title":"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay - Market Newsdesk","og_description":"Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) &#8212; Predictive Oncology Inc.\u00a0(NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx\u00ae drug response assay in Europe and expanded availability in the United States. The ChemoFx\u00ae treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time. The ChemoFx\u00ae drug response assay is a treatment selection marker for chemotherapies that quantifies an individual cancer patients\u2019 in vitro tumor response to &hellip; Continue reading \"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-16T13:07:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay","datePublished":"2025-01-16T13:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/"},"wordCount":752,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/","name":"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=","datePublished":"2025-01-16T13:07:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjg0NCM2Njk2NzI0IzIwMTkyMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/predictive-oncology-announces-planned-european-launch-of-its-chemofx-treatment-selection-marker-and-tumor-profiling-assay\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Predictive Oncology Announces Planned European Launch of its ChemoFx\u00ae Treatment Selection Marker and Tumor Profiling Assay"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=801521"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=801521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=801521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=801521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}